Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 4:27 AM
Ignite Modification Date: 2025-12-26 @ 3:30 AM
NCT ID: NCT03745820
Description: The safety population included all randomized participants who received at least 1 dose of study treatment(BIIB104 or placebo).One participant randomized to placebo,inadvertently received one or more doses of active treatment. For participants affected, a participant was counted only once within each system organ class/preferred term/study period.
Frequency Threshold: 5
Time Frame: From first dose of study drug through end of the study (up to Week 14)
Study: NCT03745820
Study Brief: A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Participants received BIIB104 matching placebo capsules, BID, orally for 12 weeks. 0 None 1 63 2 63 View
BIIB104 0.15 mg Participants received 0.15 mg capsules of BIIB104, BID, orally for 12 weeks. 0 None 1 66 2 66 View
BIIB104 0.5 mg Participants received 0.5 mg capsules of BIIB104, BID, orally for 12 weeks. 0 None 2 66 8 66 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Appendicitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA25.0 View
Schizophrenia SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA25.0 View
Psychiatric decompensation SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA25.0 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA25.0 View
Schizophrenia SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA25.0 View